Circulating complement‐1q tumor necrosis factor‐α‐related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin

Circulating complement‐1q tumor necrosis factor‐α‐related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin

Abstract Aims/Introduction As a member of the tumor necrosis factor‐α‐related protein family, complement‐1q tumor necrosis factor‐α‐related protein isoform 5 (CTRP5) has been found to be associated with obesity and insulin resistance (IR). Previous studies in humans and animals have reported contrad...

Full description

Bibliographic Details
Main Authors:	Cheng Zhang, Yong Luo, Rui Liu, Xiaoqiang Li, Mengliu Yang, Yu Zhang, Ling Li, Huaming Mou, Lian Guo, Jing Li, Hua Liu, Gangyi Yang, Xianxiang Zhang
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of Diabetes Investigation
Subjects:	Complement‐1q tumor necrosis factor‐α‐related protein isoform 5 Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes mellitus
Online Access:	https://doi.org/10.1111/jdi.13069

Similar Items

Blood glucose levels and bodyweight change after dapagliflozin administration
by: Hyunah Kim, et al.
Published: (2021-09-01)

Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
by: Jing Xu, et al.
Published: (2021-06-01)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
by: Kyu Yong Cho, et al.
Published: (2021-07-01)

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
by: Xiaodong Peng, et al.
Published: (2020-08-01)

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial
by: Hajime Yamakage, et al.
Published: (2020-05-01)

Early administration of dapagliflozin preserves pancreatic β‐cell mass through a legacy effect in a mouse model of type 2 diabetes
by: Ayumi Kanno, et al.
Published: (2019-05-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
by: Dug-Hyun Choi, et al.
Published: (2018-09-01)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
by: Fumitaka Soga, et al.
Published: (2018-10-01)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
by: Benedetta Maria Bonora, et al.
Published: (2019-08-01)

Isoform Specific Effects of Mef2C during Direct Cardiac Reprogramming
by: Li Wang, et al.
Published: (2020-01-01)

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
by: Hiroshi Tobita, MD, PhD, et al.
Published: (2017-01-01)

Contribution of the CK2 Catalytic Isoforms α and α’ to the Glycolytic Phenotype of Tumor Cells
by: Francesca Zonta, et al.
Published: (2021-01-01)

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
by: Hiroki Nakajima, et al.
Published: (2018-03-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
by: Yi-Hsuan Lin, et al.
Published: (2019-11-01)

Differential roles of PML isoforms
by: Sébastien eNisole, et al.
Published: (2013-05-01)

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
by: Yuze Zhang, et al.
Published: (2021-06-01)

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity
by: Junichi Okada, et al.
Published: (2020-01-01)

Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
by: Hidekazu Tanaka, et al.
Published: (2020-01-01)

The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma
by: Simon Keane, et al.
Published: (2021-03-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Alternatively Splicing Interactomes Identify Novel Isoform-Specific Partners for NSD2
by: Weidi Wang, et al.
Published: (2021-02-01)

Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases
by: Katherine eLintner, et al.
Published: (2016-02-01)

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
by: Zvi Fishelson, et al.
Published: (2019-04-01)

RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer
by: Ming Li, et al.
Published: (2020-05-01)

Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform
by: Xianling Ning, et al.
Published: (2018-01-01)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2
by: Alexia Martínez de Paz, et al.
Published: (2019-10-01)

Obtención de un preparado del componente C1 (q,r,s) del sistema complemento Obtaining a preparation of C1 component (q,r,s) of the complement system
by: Julio C Merlín Linares, et al.
Published: (2002-12-01)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
by: Damas-Fuentes, M., et al.
Published: (2022)

On certain quasi-complemented and complemented Banach algebras
by: Pak-Ken Wong
Published: (1978-01-01)

A Comparative Analysis of Hydrolysis Kinetics by sPLA2 Isoforms During Apoptosis in S49 Cells
by: Olson, Erin Dalene
Published: (2008)

The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo
by: Fiona H. X. Guan, et al.
Published: (2017-03-01)

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
by: Megumi Yasuda, et al.
Published: (2020-05-01)

Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer
by: Yu Sato, et al.
Published: (2020-09-01)

Characterization of isoform specific RET knockdown in cancer cell lines
by: Lian, ERIC
Published: (2013)

Characteristics of Human OAS1 Isoform Proteins
by: Han Di, et al.
Published: (2020-01-01)

Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
by: Sanjay Kalra, et al.
Published: (2017-01-01)

Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway
by: Jeong-Tae Yeon, et al.
Published: (2012-03-01)